Mild to moderate, progressive keratoconus patients undergoing epithelium-off corneal collagen crosslinking or healthy mild to moderate myopic control patients undergoing photorefractive keratectomy were selected based on clinical examination and Scheimpflug tomography (Pentacam, Oculus, Germany; see
Supplementary Table S1 for keratoconus patients’ clinical characteristics). Specifically, in order to treat progressive cases as early as possible, eyes were defined as having progressive keratoconus if there was a documented increase in steepest central keratometry or maximal keratometry on corneal tomography of 0.4 diopters over 3 to 4 months or more than 1 diopter a year. Patients 25 years or younger with evidence of keratoconus on tomography and distance spectacle-corrected vision 20/25 or worse were also defined as having progressive disease. Importantly, keratoconus was ruled out in all control patients prior to study enrollment.
For the purpose of the RNA and western blot studies described herein, corneal epithelial samples were acquired during corneal collagen crosslinking or photorefractive keratectomy. These samples were obtained in a sterile fashion after topical application of proparacaine HCl 0.5% ophthalmic drops (Bausch & Lomb, Rochester, NY, USA) and 5% betadine ophthalmic solution (Alcon, Fort Worth, TX, USA). A 9-mm metal well was placed on the central cornea avoiding the limbus, and 20% alcohol was applied for 30 seconds to facilitate epithelial removal. The alcohol was removed with cellulose sponges followed by thorough irrigation with balanced salt solution. The central epithelia were promptly debrided with sterile cellulose sponges and immediately placed in the operating room into individual RNAlater tubes (Thermo Fisher, Waltham, MA, USA). Samples were kept refrigerated (4°C) in RNAlater for 48 hours and then frozen at −80°C. The samples were homogenized with sterile individual tips (Tissueruptur II; Qiagen, Hilden, Germany). RNA was extracted using the RNAeasy Plus kit (Qiagen). RNA quality was checked with a Nanodrop (Thermo Fisher) and a bioanalyzer nano RNA chip (Agilent, Santa Clara, CA, USA). Samples with a RNA Integrity Number (RIN) score over 8 were used for RNA-seq. RNA-seq was performed on corneal epithelium derived from five keratoconus and five myopic controls. Library preparation was performed according to the manufacturer's instructions with the TruSeq Stranded Library prep protocol (Illumina, San Diego, CA, USA) at the Johns Hopkins School of Medicine sequencing core. Sequencing was paired-end 75 nucleotides with a total target of 400 million reads on the Illumina NextSeq 500 High 150 Output sequencing instrument (40 million reads per sample). The libraries were sequenced to provide FASTA raw data.